Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced colorectal carcinoma.
Progression on prior oxaliplatin-containing regimen used in 1st line setting for mCRC or progression within 6 months of end of oxaliplatin-containing regimen in the adjuvant setting.
Tumor tissue available at time of screening for molecular profiling.
Adequate performance status.
Adequate glucose control, bone marrow, kidney, liver, and heart function.
You may not be if
Participation in other studies involving investigational drug(s) (Phases 1-4) before the current study begins and/or during study participation.
Prior irinotecan treatment.
Prior radiation to the pelvis or abdomen in the metastatic or locally advanced setting.
History of Gilbert's syndrome.
Active brain metastases.
Deep vein thrombosis in the preceding 2 months.
History of interstitial lung disease.
RAS (KRAS/NRAS) wild type mCRC not previously treated with an anti-EGFR containing regimen (unless contraindicated or not considered standard practice per clinical site or country guidelines).
Clareo Health | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
